Notably, the rates of irAEs reported in patients with AML and HR-MDS treated in trials using PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors are similar to those observed with solid tumors [53,54]. This evidence concerns the gene CD274 and myelodysplastic syndrome.